A Multicenter, Open-label Extension Study to Evaluate the Safety, Pharmacodynamics, and Clinical Effects of WVE-120101 in Patients with Huntington's Disease
Latest Information Update: 11 Feb 2022
Price :
$35 *
At a glance
- Drugs Rovanersen (Primary)
- Indications Huntington's disease
- Focus Adverse reactions
- Sponsors WaVe life Sciences
- 16 Jun 2021 Status changed from active, no longer recruiting to discontinued(The Reason was stopped due to Lack of efficacy).
- 07 May 2021 This trial has been discontinued in Denmark, according to European Clinical Trials Database record.
- 03 May 2021 This trial has been discontinued in France, according to European Clinical Trials Database record.